A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Active, not recruiting · Phase 1 · NCT06238479
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
At a glance
- Research payments reported, 2025
- $2.9M
- U.S. investigators named
- 8
- Sites paid
- 11
- Planned or actual enrollment
- 490
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY4101174 (drug)
- Dates
- Started 2024-03-05; completion 2027-04
- Results posted
- Not yet
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase 1a (dose-escalation, dose-optimization) and phase 1b (dose-expansion). The study will last up to approximately 4 years. Eligible patients will have the option to continue taking study drug after the study is complete.
From ClinicalTrials.gov, last updated 2026-05-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $2.9M in research payments for this study in 2025 (23 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Guru P. Sonpavde, MD Medical Oncology · Orlando, FL
- Jacqueline T. Brown, MD Medical Oncology · Atlanta, GA
- Xin Gao, M.D. Hematology & Oncology · Boston, MA
- Melissa A. Reimers, MD Medical Oncology · Saint Louis, MO
- Kristen R. Spencer, D.O. Medical Oncology · New Brunswick, NJ
- Jonathan E. Rosenberg, MD Medical Oncology · New York, NY
- Amita Patnaik, M.D. Medical Oncology · San Antonio, TX
- Tian Zhang, M.D. Medical Oncology · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana Farber PArtners Cancer Care Inc $817,720
- Memorial Sloan-Kettering $466,767
- The University of Texas $465,481
- Washington University $388,233
- Emory University Hospital, GA $267,302
- South Texas Accelerated Research Therapeutics LLC $206,846
- Adventhealth Orlando, FL $124,173
- New York University $116,804
- Massachusetts General Hospital, MA $7,055
- Start Ctr for Cancer Care $1,537
- University Clinical Trials Inc $357
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.